A. Arance

发表

Association of BRAF V600E/K Mutation Status and Prior BRAF/MEK Inhibition With Pembrolizumab Outcomes in Advanced Melanoma: Pooled Analysis of 3 Clinical Trials.

D. Schadendorf, P. Ascierto, R. Dummer, 2020, JAMA oncology.

ESMO consensus conference recommendations on the management of locoregional melanoma: under the auspices of the ESMO Guidelines Committee

B. Schilling, S. Puig, V. Sondak, 2020 .

Relatlimab and Nivolumab versus Nivolumab in Untreated Advanced Melanoma.

D. Schadendorf, P. Ascierto, E. Lipson, 2022, The New England journal of medicine.

Ixabepilone alone or with cetuximab as first-line treatment for advanced/metastatic triple-negative breast cancer.

R. Vyzula, M. Campone, J. Jassem, 2015, Clinical breast cancer.

TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas.

S. Puig, P. Jares, A. García-Herrera, 2020, Annals of translational medicine.

Combined PD-1, BRAF and MEK inhibition in advanced BRAF-mutant melanoma: safety run-in and biomarker cohorts of COMBI-i

D. Schadendorf, K. Flaherty, P. Ascierto, 2020, Nature Medicine.

Prognostic value of the expression of E-cadherin and beta-catenin in bladder cancer.

X. Castellsagué, E. Condom, F. Vigués, 2000, European journal of cancer.

Long-term outcomes in patients with advanced melanoma who had initial stable disease with pembrolizumab in KEYNOTE-001 and KEYNOTE-006

J. Wolchok, A. Ribas, F. Hodi, 2021, European journal of cancer.

Randomized Phase III Trial Evaluating Spartalizumab Plus Dabrafenib and Trametinib for BRAF V600–Mutant Unresectable or Metastatic Melanoma

D. Schadendorf, K. Flaherty, P. Ascierto, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

TP53 mutation and tumoral PD-L1 expression are associated with depth of invasion in desmoplastic melanomas

S. Puig, P. Jares, A. García-Herrera, 2020, Annals of translational medicine.

ESMO consensus conference recommendations on the management of locoregional melanoma: the ESMO Guidelines Committee.

B. Schilling, S. Puig, V. Sondak, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequencing of Ipilimumab Plus Nivolumab and Encorafenib Plus Binimetinib for Untreated BRAF-Mutated Metastatic Melanoma (SECOMBIT): A Randomized, Three-Arm, Open-Label Phase II Trial

D. Mallardo, P. Ascierto, R. Dummer, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II LEAP-004 Study of Lenvatinib Plus Pembrolizumab for Melanoma With Confirmed Progression on a Programmed Cell Death Protein-1 or Programmed Death Ligand 1 Inhibitor Given as Monotherapy or in Combination

A. Carneiro, G. Long, L. Ny, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE).

M. Lux, R. Greil, A. Schneeweiss, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO consensus conference recommendations on the management of metastatic melanoma: the ESMO Guidelines Committee.

B. Schilling, S. Puig, V. Sondak, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

ESMO consensus conference recommendations on the management of metastatic melanoma: under the auspices of the ESMO Guidelines Committee

B. Schilling, S. Puig, V. Sondak, 2020 .

COLUMBUS 5-Year Update: A Randomized, Open-Label, Phase III Trial of Encorafenib Plus Binimetinib Versus Vemurafenib or Encorafenib in Patients With BRAF V600–Mutant Melanoma

D. Schadendorf, K. Flaherty, P. Ascierto, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Successful management of refractory immune-mediated enterocolitis with cyclosporine.

I. Ordás, E. Seguí, D. Pesántez, 2020, European journal of cancer.

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

A. Ribas, F. Hodi, J. Schachter, 2018, British Journal of Cancer.

1091PDCOMBI-D: QUALITY OF LIFE (QOL) IMPACT OF THE COMBINATION OF DABRAFENIB AND TRAMETINIB (D + T) VERSUS DABRAFENIB MONOTHERAPY (D) IN PATIENTS WITH BRAF V600E/K UNRESECTABLE OR METASTATIC MELANOMA IN A PHASE III TRIAL.

D. Schadendorf, M. Casey, C. Garbe, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

SOLTI-1904 ACROPOLI TRIAL: efficacy of spartalizumab monotherapy across tumor-types expressing high levels of PD1 mRNA.

M. Juan, E. Felip, J. Tabernero, 2022, Future oncology.

Vemurafenib in patients with BRAF(V600) mutated metastatic melanoma: an open-label, multicentre, safety study.

A. Hauschild, P. Ascierto, J. Larkin, 2014, The Lancet. Oncology.

The anti–PD-1 antibody spartalizumab (S) in combination with dabrafenib (D) and trametinib (T) in previously untreated patients (pts) with advanced BRAF V600–mutant melanoma: Updated efficacy and safety from parts 1 and 2 of COMBI-I.

D. Schadendorf, K. Flaherty, P. Ascierto, 2019, Journal of Clinical Oncology.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial

J. Utikal, A. Hauschild, D. Schadendorf, 2015, The Lancet.

Cobimetinib plus atezolizumab in BRAFV600 wild-type melanoma: primary results from the randomized phase 3 IMspire170 study.

K. Flaherty, J. Larkin, H. Gogas, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Life-threatening colitis and complete response with ipilimumab in a patient with metastatic BRAF-mutant melanoma and rheumatoid arthritis

J. Malvehy, A. Prat, E. Pineda, 2016, ESMO Open.

Update on tolerability and overall survival in COLUMBUS: landmark analysis of a randomised phase 3 trial of encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600-mutant melanoma.

D. Schadendorf, K. Flaherty, P. Ascierto, 2020, European journal of cancer.

D. Schadendorf, K. Flaherty, J. Larkin, 2015, European journal of cancer.

Avelumab expanded access program in metastatic Merkel cell carcinoma: Efficacy and safety findings from patients in Europe and the Middle East

P. Ascierto, V. Chiarion Sileni, P. Lorigan, 2021, International journal of cancer.

Molecular Markers and Targets in Melanoma

L. Alós, P. Castillo, C. Teixidó, 2021, Cells.

A Retrospective Analysis of Dabrafenib and/or Dabrafenib Plus Trametinib Combination in Patients with Metastatic Melanoma to Characterize Patients with Long-Term Benefit in the Individual Patient Program (DESCRIBE III)

P. Ascierto, M. Del Vecchio, I. Krajsová, 2021, Cancers.

Rechallenge with BRAF-directed treatment in metastatic melanoma: A multi-institutional retrospective study.

M. Weichenthal, A. Hauschild, D. Schadendorf, 2018, European journal of cancer.

Antitumour activity of pembrolizumab in advanced mucosal melanoma: a post-hoc analysis of KEYNOTE-001, 002, 006

A. Ribas, F. Hodi, J. Schachter, 2018, British Journal of Cancer.

Adjuvant nivolumab for stage III/IV melanoma: evaluation of safety outcomes and association with recurrence-free survival

P. Ascierto, M. Del Vecchio, M. Mandalà, 2021, Journal for ImmunoTherapy of Cancer.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study

J. Utikal, A. Hauschild, D. Schadendorf, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

The anti–PD-1 antibody spartalizumab in combination with dabrafenib and trametinib in advanced BRAF V600–mutant melanoma: Efficacy and safety findings from parts 1 and 2 of the Phase III COMBI-i trial.

D. Schadendorf, K. Flaherty, P. Ascierto, 2020 .

Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

P. Ascierto, A. Arance, M. Mandalà, 2019, Annals of Oncology.

Efficacy and safety of immune checkpoint inhibitors in young adults with metastatic melanoma.

D. Schadendorf, S. Ugurel, R. Sullivan, 2022, European journal of cancer.

A randomized, open-label, phase II open platform study evaluating the efficacy and safety of novel spartalizumab (PDR001) combinations in previously treated unresectable or metastatic melanoma (PLATForM).

D. Schadendorf, P. Ascierto, A. Boran, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic BRAF-Mutant Melanoma

R. Sullivan, M. Hidalgo, G. Caponigro, 2017, Clinical Cancer Research.

Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts

Hosein, Inge, P. Ascierto, 2019, Journal of Translational Medicine.

Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.

J. Utikal, A. Hauschild, D. Schadendorf, 2019 .

Breast cancer, locally advanced and metastatic

L. Holmberg, O. Nanni, S. Barni, 2012 .

Contribution of MEK Inhibition to BRAF/MEK Inhibitor Combination Treatment of BRAF-Mutant Melanoma: Part 2 of the Randomized, Open-Label, Phase III COLUMBUS Trial

D. Schadendorf, K. Flaherty, P. Ascierto, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study

A. Hauschild, D. Schadendorf, R. Gonzalez, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall Survival and Response with Nivolumab and Relatlimab in Advanced Melanoma

D. Schadendorf, P. Ascierto, E. Lipson, 2023, NEJM Evidence.

Re-challenge with BRAF-directed treatment: A multi-institutional retrospective study.

M. Weichenthal, A. Hauschild, D. Schadendorf, 2017 .

1244PHospitalization Rates in COLUMBUS Part 1: A Phase 3 Trial of Encorafenib (ENCO) Plus Binimetinib (BINI) Versus Vemurafenib (VEM) or ENCO in BRAF-Mutant Melanoma

D. Schadendorf, K. Flaherty, P. Ascierto, 2017 .

D. Schadendorf, K. Flaherty, J. Larkin, 2015, European Journal of Cancer.

Discontinuation of anti-PD-1 antibody therapy in the absence of disease progression or treatment limiting toxicity: clinical outcomes in advanced melanoma.

R. Dummer, E. Rozeman, H. Schmidt, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

Sequential immunotherapy and targeted therapy for metastatic BRAF V600 mutated melanoma: 4-year survival and biomarkers evaluation from the phase II SECOMBIT trial

D. Mallardo, P. Ascierto, M. Del Vecchio, 2024, Nature communications.

Epacadostat (E) plus pembrolizumab (P) versus pembrolizumab alone in patients (pts) with unresectable or metastatic melanoma: Results of the phase 3 ECHO-301/KEYNOTE-252 study.

James R. Anderson, R. Dummer, J. Larkin, 2018 .

Immunotherapy Bridge 2018 and Melanoma Bridge 2018: meeting abstracts

Hosein, Inge, P. Ascierto, 2019, Journal of Translational Medicine.

535PENCORAFENIB (LGX818), AN ORAL BRAF INHIBITOR, IN PATIENTS (PTS) WITH BRAF V600E METASTATIC COLORECTAL CANCER (MCRC): RESULTS OF DOSE EXPANSION IN AN OPEN-LABEL, PHASE 1 STUDY.

M. Hidalgo, J. Tabernero, A. Arance, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Feasibility and Impact of Embedding an Extended DNA and RNA Tissue-Based Sequencing Panel for the Routine Care of Patients with Advanced Melanoma in Spain

G. Clot, L. Alós, Mireia García, 2024, International journal of molecular sciences.

Lymphocyte T Subsets and Outcome of Immune Checkpoint Inhibitors in Melanoma Patients: An Oncologist’s Perspective on Current Knowledge

A. Arance, F. Aya, E. A. González-Navarro, 2024, International Journal of Molecular Sciences.

Efficacy and safety of nilotinib in patients with KIT-mutated metastatic or inoperable melanoma: final results from the global, single-arm, phase II TEAM trial

C. Berking, A. Hauschild, D. Schadendorf, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Seven-Year Follow-Up of the Phase III KEYNOTE-006 Study: Pembrolizumab Versus Ipilimumab in Advanced Melanoma

A. Ribas, J. Schachter, J. Grob, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

COLUMBUS 7-year update: A randomized, open-label, phase III trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF V600E/K-mutant melanoma.

P. Ascierto, I. Krajsová, A. Arance, 2024, European journal of cancer.